Supplemental Financial Information (Tables)

12 Months Ended

Dec. 31, 2024

Balance Sheet Related Disclosures [Abstract]

Schedule of Property, Plant and Equipment Net

Property, plant and equipment, net consisted of the following (in thousands):

	December 31, 2024			December 31, 2023
Leasehold improvements	$	2,117		$	2,117
Laboratory equipment		3,130			2,868
Computer equipment		707			1,133
Furniture and fixtures		864			864
Construction in progress		4,251			6,823
		11,069			13,805
Accumulated depreciation		(3,584	)		(2,979	)
Property, plant and equipment, net	$	7,485		$	10,826

Schedule of Accrued Expenses and Other Current Labilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	December 31, 2024		December 31, 2023
Accrued compensation	$	5,242	$	3,423
Accrued clinical trial		1,907		1,851
Lease liabilities, current portion		1,877		1,646
Accrued research and development		1,714		3,467
Accrued professional and consulting fees		725		330
Warrant liability		438		454
Accrued property, plant and equipment		207		—
Accrued severance		—		390
Other		752		723
Total accrued expenses and other current liabilities	$	12,862	$	12,284

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	December 31, 2024		December 31, 2023
Prepaid clinical trial	$	1,112	$	802
Prepaid research and development		841		1,412
Prepaid insurance		249		292
Deferred offering costs		135		681
Other		308		292
Total prepaid expenses and other current assets	$	2,645	$	3,479